• About
  • Subscribe
  • Advertise
  • Contact
Thursday, December 5, 2024
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Ophthalmic insights Clinical trials

Positive results for Azura Ophthalmics investigational dry eye therapy

by Staff Writer
January 8, 2024
in Clinical trials, Dry eye, Eye disease, News, Ophthalmic insights
Reading Time: 3 mins read
A A
Azura dry eye

During the trial, patients gained at least three hours of comfortable contact lens wear time daily. Image: Adobe Stock/Мар'ян Філь

Share on FacebookShare on Twitter

Melbourne-linked biopharmaceutical company Azura Ophthalmics has announced positive results from a Phase 2 clinical trial of its investigational dry eye therapy AZR-MD-001 in patients with contact lens discomfort (CLD).

The multicentre, vehicle-controlled study achieved topline efficacy and safety results at three months.

Sixty-seven participants were recruited who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD), a leading cause of dry eye disease and CLD.

The trial met its primary endpoint of showing a statistically significant improvement in number of open meibomian glands. Patients in the AZR-MD-001 arm gained at least three hours of comfortable contact lens wear time daily.

The study also met additional secondary and clinically meaningful endpoints, including significant improvements in meibum quality, tear stability, ocular surface staining and contact lens wear time. AZR-MD-001 was also reported to be safe and well tolerated with all observed adverse events being mild to moderate in severity and none resulting in treatment discontinuation.

Azura said this is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

“MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including contact lens discomfort. By opening up blocked glands and improving the quality of the tear film, we believe many of these ocular surface conditions can be resolved,” Mr Marc Gleeson, CEO of Azura, said.

“In addition to meeting its primary MGYLS endpoint, we are especially encouraged that AZD-MD-001 allowed patients who had given up using contacts to wear their contacts again – safely and comfortably – for an additional three hours every day over their normal wear time. We now have two studies showing AZR-MD-001 can improve the signs and symptoms of MGD and we look forward to discussing these results with the FDA as we advance our Phase 3 development program.”

Mr Lyndon Jones, director and professor at the Centre for Ocular Research & Education in Ontario, Canada, said that many patients have given up on wearing contact lenses altogether due to discomfort and with innovation in this space stalling, AZR-MD-001 addresses this by treating the underlying causes of CLD.

“With these AZR-MD-001 data, I’m encouraged to see a potential treatment that may address the underlying cause of contact lens discomfort, and I believe my patients would find an extra three hours of comfortable contact lens wear time to be very meaningful.”

Azura is expecting to advance AZR-MD-001 into Phase 3 studies.

More reading

Phase 2b results for Azura Ophthalmics meibomian gland dysfunction therapy

New research supports potential prescription treatment for dry eye disease

Re-writing the rules of dry eye management

Related Posts

A new WA clinic will give Aboriginal communities and others greater access to eyecare. Image: Sawoon/stock.adobe.com

New clinic will help address inequities in Aboriginal eyecare

by Staff Writer
December 5, 2024

A new eye clinic aims to make a significant impact in transforming eyecare for Aboriginal communities in Western Australia. A...

Or lack of it, depending on where you live, is the concern of the CPMC and others. Image: BJP7images/stock.adobe.com.

Health ministers warned that fast-track changes could bring ‘postcode’ health care

by Staff Writer
December 5, 2024

Australia’s state health ministers have been warned that the proposed fast-track registration of Specialist International Medical Graduates (SIMGs) risks exacerbating...

Alcon has confirmed its new Unity systems are now registered in Australia, and will be commercially available in 2025. Image: Konektus Photo/Shutterstock.com.

All-new Alcon Unity vitreoretinal and cataract systems approved in Australia

by Myles Hume
December 4, 2024

Alcon has revealed its “highly anticipated” Unity Vitreoretinal Cataract System and Unity Cataract System have been included on the Australian...

Join our newsletter

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited